Physician profile
Eric N Brewer
NPI 1275957912
$7,877.72
in general payments reported to CMS, 2019-2025
39 companies · $2,013 in 2025
The $2,013 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,504 · 2022: $1,339 · 2023: $1,248 · 2024: $1,774 · 2025: $2,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,798 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,797.88 |
| Education | $236.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,483.58 | 2021-2025 | |
| Novo Nordisk INC | $1,329.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $693.37 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $692.05 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $412.74 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Antares Pharma, INC. | $384.63 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Takeda Pharmaceuticals U.S.A., INC. | $329.68 | 2021-2025 | Trintellix |
| Astellas Pharma US INC | $329.40 | 2023-2025 | Veozah |
| Abbott Laboratories | $301.53 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $289.84 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $206.01 | 2024-2025 | Voquezna |
| Amgen INC. | $165.22 | 2021-2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.89 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $104.14 | 2021-2023 | Belsomra, Steglatro |
| Biohaven Pharmaceuticals, INC. | $99.39 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.